Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases.
OBJECTIVE
Benign prostatic hyperplasia and prostate cancer are important public health issues. However, histologic markers for these diseases are limited.


METHODS
Immunocytochemistry was used to analyze the cellular localization of AIbZIP, Cdc47, androgen receptor and estrogen receptor-beta markers. AIbZIP is a protein recently found to be more abundant in prostate cancer than in benign prostatic tissue, and Cdc47 is a cell proliferation-associated protein. The localization and modulation of androgen receptor and estrogen receptor-beta through the carcinogenesis process have been examined in several studies but controversial results were obtained. These four proteins were evaluated as potential markers of prostatic diseases in 210 needle core biopsies, including normal prostate, benign prostatic hyperplasia, low-grade and high-grade prostatic intraepithelial neoplasia, and different Gleason grades of prostatic adenocarcinoma.


RESULTS
Androgen receptor and estrogen receptor-beta do not discriminate between benign and malignant specimens, while AIbZIP was able to distinguish between them. Cdc47, in contrast, discriminated not only between malignant and benign prostatic tissue, but also between benign prostatic hyperplasia and normal prostatic tissue.


CONCLUSIONS
Cdc47 appears to be a sensitive marker of prostatic diseases since its expression gradually increased in parallel with the severity of the lesion. AIbZIP discriminated between benign tissue and cancer. AIbZIP and Cdc47 thus appear to be useful markers with diagnostic and prognostic values.
Levesque
Marie-Hélène
MH
Molecular Endocrinology and Oncology Research Center, Laval University Hospital Research Center, Quebec City, Quebec, Canada.
El-Alfy
Mohamed
M
Berger
Louise
L
Labrie
Fernand
F
Labrie
Claude
C
D000368:Aged; D000369:Aged, 80 and over; D050976:Basic-Leucine Zipper Transcription Factors / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis; D018797:Cell Cycle Proteins / Q000032:analysis*; D049109:Cell Proliferation; D017362:Cyclic AMP Response Element-Binding Protein; D004268:DNA-Binding Proteins / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D064168:Minichromosome Maintenance Complex Component 7; D009687:Nuclear Proteins / Q000032:analysis*; D011467:Prostate / Q000737:chemistry* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000473:pathology; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000473:pathology
D050976:Basic-Leucine Zipper Transcription Factors; D015415:Biomarkers; C448322:CREB3L4 protein, human; D018797:Cell Cycle Proteins; D017362:Cyclic AMP Response Element-Binding Protein; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; C101624:MCM7 protein, human; D064168:Minichromosome Maintenance Complex Component 7